National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Ixazomib is indicated in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

Rapid Review

Commenced Completed Outcome
23/11/2016 16/01/2017 Full Pharmacoeconomic Evaluation Recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
01/06/2017   HTA in progress